a 2018

A quarter of NRAS positive patients carry multiple point mutations, each of them localised separately in different alleles

ĎURINÍKOVÁ, Anna, Ivana JEŽÍŠKOVÁ, A. FOLTA, Dagmar AL TUKMACHI, Zdeňka HERUDKOVÁ et. al.

Basic information

Original name

A quarter of NRAS positive patients carry multiple point mutations, each of them localised separately in different alleles

Authors

ĎURINÍKOVÁ, Anna (703 Slovakia, belonging to the institution), Ivana JEŽÍŠKOVÁ (203 Czech Republic, belonging to the institution), A. FOLTA (203 Czech Republic), Dagmar AL TUKMACHI (203 Czech Republic, belonging to the institution), Zdeňka HERUDKOVÁ (203 Czech Republic, belonging to the institution), Martin ČULEN (703 Slovakia, belonging to the institution), Dana DVOŘÁKOVÁ (203 Czech Republic, belonging to the institution), Nikola TOM (203 Czech Republic, belonging to the institution), P. CETKOVSKÝ (203 Czech Republic), P. JINDRA (203 Czech Republic), T. SZOTKOWSKI (203 Czech Republic), P. ŽÁK (203 Czech Republic), Jiří MAYER (203 Czech Republic, belonging to the institution) and Zdeněk RÁČIL (203 Czech Republic, guarantor, belonging to the institution)

Edition

23rd Congress of the European Hematology Association, Stockholm, Sweden in HemaSphere, 2018

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

10606 Microbiology

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14740/18:00104471

Organization unit

Central European Institute of Technology

Keywords in English

NRAS; mutations; localised separately

Tags

Změněno: 26/3/2019 15:38, Mgr. Pavla Foltynová, Ph.D.

Abstract

V originále

A quarter of NRAS positive patients carry multiple point mutations, each of them localised separately in different alleles, A quarter of NRAS positive patients carry multiple point mutations, each of them localised separately in different alleles.

Links

MUNI/A/0968/2017, interní kód MU
Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit V (Acronym: VýDiTeHeMA V)
Investor: Masaryk University, Category A